New hope for elderly lung cancer patients: drug combo targets tough cases
NCT ID NCT07398560
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs (adebrelimab and oral etoposide) in elderly or frail patients with small cell lung cancer. The goal is to see if this treatment can slow down the cancer's growth and improve outcomes. About 47 participants will receive the treatment, and researchers will monitor how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Third Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells boost lung cancer remission?
- Could adding chest radiation extend life in advanced lung cancer?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Can a new drug tame advanced solid tumors?
- Can a remote approach bring clinical trials to lung cancer patients?
- Which palliative care approach boosts quality of life in advanced lung cancer?